Drug Profile
Research programme: skin disorder therapeutics - Dermadis
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Dermadis
- Class Biological peptides; Biological proteins
- Mechanism of Action Peptide inhibitors; Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Skin-disorders in France
- 28 Feb 2010 Early research in Skin disorders in France (unspecified route)